Department of Neurological Sciences, The Robert Larner, M.D. College of Medicine at The University of Vermont, Given Building, D405A, Burlington, VT, 05405, USA.
J Mol Neurosci. 2019 Jul;68(3):357-367. doi: 10.1007/s12031-018-1170-7. Epub 2018 Sep 27.
Neural injury, inflammation, or diseases commonly and adversely affect micturition reflex function that is organized by neural circuits in the CNS and PNS. One neuropeptide receptor system, pituitary adenylate cyclase-activating polypeptide (PACAP; Adcyap1), and its cognate receptor, PAC1 (Adcyap1r1), have tissue-specific distributions in the lower urinary tract. PACAP and associated receptors are expressed in the LUT and exhibit changes in expression, distribution, and function in preclinical animal models of bladder pain syndrome (BPS)/interstitial cystitis (IC), a chronic, visceral pain syndrome characterized by pain, and LUT dysfunction. Blockade of the PACAP/PAC1 receptor system reduces voiding frequency and somatic (e.g., hindpaw, pelvic) sensitivity in preclinical animal models and a transgenic mouse model that mirrors some clinical symptoms of BPS/IC. The PACAP/receptor system in micturition pathways may represent a potential target for therapeutic intervention to reduce LUT dysfunction following urinary bladder inflammation.
神经损伤、炎症或疾病通常会对由中枢神经系统和周围神经系统中的神经回路组织的排尿反射功能产生不利影响。一种神经肽受体系统,垂体腺苷酸环化酶激活肽(PACAP;Adcyap1)及其同源受体 PAC1(Adcyap1r1),在下尿路中具有组织特异性分布。PACAP 和相关受体在 LUT 中表达,并在膀胱疼痛综合征 (BPS)/间质性膀胱炎 (IC) 的临床前动物模型中表现出表达、分布和功能的变化,BPS/IC 是一种以疼痛和 LUT 功能障碍为特征的慢性内脏疼痛综合征。在临床前动物模型和模拟 BPS/IC 一些临床症状的转基因小鼠模型中,阻断 PACAP/PAC1 受体系统可减少排尿频率和躯体(例如,后足、骨盆)敏感性。排尿途径中的 PACAP/受体系统可能代表治疗干预的潜在靶点,以减少膀胱炎症后 LUT 功能障碍。
J Mol Neurosci. 2018-9-27
Front Syst Neurosci. 2017-12-4
Am J Physiol Regul Integr Comp Physiol. 2006-4
Int J Mol Sci. 2024-7-24
Front Endocrinol (Lausanne). 2020
Front Syst Neurosci. 2017-12-4
Arch Gynecol Obstet. 2017-6
Transl Androl Urol. 2015-10
Handb Exp Pharmacol. 2015